Matches in SemOpenAlex for { <https://semopenalex.org/work/W2465789506> ?p ?o ?g. }
- W2465789506 endingPage "263" @default.
- W2465789506 startingPage "254" @default.
- W2465789506 abstract "ObjectivePulmonary arterial hypertension (PAH) is a condition which may lead to right ventricular failure and early mortality and is an important complication in patients with connective tissue disease (CTD). Previously, the endothelin A selective receptor antagonist, ambrisentan, demonstrated efficacy and safety in treating patients with PAH due to WHO Group I etiologies. These analyses describe the 3-year efficacy and safety of ambrisentan in patients specifically with CTD associated PAH (CTD-PAH).MethodsPatients with CTD-PAH participating in the ARIES-1 and -2 clinical trials and their long-term extension were evaluated. Efficacy evaluations including 6-min walk distance (6MWD), clinical worsening, and survival were collected at routine study visits. Additional analyses of 6MWD categorical (30 m) breakpoints were conducted to determine any relationship between 6MWD and a prognostic threshold for survival.Results124 patients with CTD-PAH were evaluated. 62.6%, 57.3%, and 58.2% of CTD-PAH patients treated with ambrisentan exhibited increases in 6MWD at 1-, 2-, and 3- years respectively. At 3 years, 64% of patients were free from clinical worsening and 76% of patients were still alive (Kaplan-Meier estimates). Identified factors holding prognostic relevance for survival include: baseline functional class, CTD-PAH subgroup, patient sex, improvement in 6MWD ≥30 m over the first 12 weeks of treatment, the most recent 6MWD, and a 6MWD absolute threshold of 222 m.ConclusionThese first analyses of the 3-year treatment of CTD-PAH patients with ambrisentan revealed fewer clinical worsening events and improved survival compared to historical controls. Key exercise parameters were also identified which appear important in guiding treatment." @default.
- W2465789506 created "2016-07-22" @default.
- W2465789506 creator A5008098676 @default.
- W2465789506 creator A5009975917 @default.
- W2465789506 creator A5034366220 @default.
- W2465789506 creator A5038098413 @default.
- W2465789506 creator A5039032334 @default.
- W2465789506 creator A5052485494 @default.
- W2465789506 creator A5067862295 @default.
- W2465789506 date "2016-08-01" @default.
- W2465789506 modified "2023-10-18" @default.
- W2465789506 title "Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) – A subgroup analysis of the ARIES-E clinical trial" @default.
- W2465789506 cites W1975615159 @default.
- W2465789506 cites W1984693219 @default.
- W2465789506 cites W1985526821 @default.
- W2465789506 cites W2004950293 @default.
- W2465789506 cites W2011870650 @default.
- W2465789506 cites W2018071189 @default.
- W2465789506 cites W2018621622 @default.
- W2465789506 cites W2037489482 @default.
- W2465789506 cites W2051069436 @default.
- W2465789506 cites W2061321731 @default.
- W2465789506 cites W2070897020 @default.
- W2465789506 cites W2078345891 @default.
- W2465789506 cites W2096352797 @default.
- W2465789506 cites W2100418954 @default.
- W2465789506 cites W2101733459 @default.
- W2465789506 cites W2110637500 @default.
- W2465789506 cites W2129099016 @default.
- W2465789506 cites W2129125190 @default.
- W2465789506 cites W2132978366 @default.
- W2465789506 cites W2135510321 @default.
- W2465789506 cites W2136245768 @default.
- W2465789506 cites W2143819380 @default.
- W2465789506 cites W2160056424 @default.
- W2465789506 cites W2171108647 @default.
- W2465789506 cites W2315855923 @default.
- W2465789506 doi "https://doi.org/10.1016/j.rmed.2016.06.018" @default.
- W2465789506 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27492539" @default.
- W2465789506 hasPublicationYear "2016" @default.
- W2465789506 type Work @default.
- W2465789506 sameAs 2465789506 @default.
- W2465789506 citedByCount "24" @default.
- W2465789506 countsByYear W24657895062017 @default.
- W2465789506 countsByYear W24657895062018 @default.
- W2465789506 countsByYear W24657895062019 @default.
- W2465789506 countsByYear W24657895062020 @default.
- W2465789506 countsByYear W24657895062021 @default.
- W2465789506 countsByYear W24657895062022 @default.
- W2465789506 countsByYear W24657895062023 @default.
- W2465789506 crossrefType "journal-article" @default.
- W2465789506 hasAuthorship W2465789506A5008098676 @default.
- W2465789506 hasAuthorship W2465789506A5009975917 @default.
- W2465789506 hasAuthorship W2465789506A5034366220 @default.
- W2465789506 hasAuthorship W2465789506A5038098413 @default.
- W2465789506 hasAuthorship W2465789506A5039032334 @default.
- W2465789506 hasAuthorship W2465789506A5052485494 @default.
- W2465789506 hasAuthorship W2465789506A5067862295 @default.
- W2465789506 hasBestOaLocation W24657895061 @default.
- W2465789506 hasConcept C111368507 @default.
- W2465789506 hasConcept C125533998 @default.
- W2465789506 hasConcept C126322002 @default.
- W2465789506 hasConcept C127313418 @default.
- W2465789506 hasConcept C144980905 @default.
- W2465789506 hasConcept C164705383 @default.
- W2465789506 hasConcept C170493617 @default.
- W2465789506 hasConcept C187960798 @default.
- W2465789506 hasConcept C2776670291 @default.
- W2465789506 hasConcept C2779075594 @default.
- W2465789506 hasConcept C2779134260 @default.
- W2465789506 hasConcept C2780263000 @default.
- W2465789506 hasConcept C2780930700 @default.
- W2465789506 hasConcept C2781109936 @default.
- W2465789506 hasConcept C44249647 @default.
- W2465789506 hasConcept C535046627 @default.
- W2465789506 hasConcept C71924100 @default.
- W2465789506 hasConceptScore W2465789506C111368507 @default.
- W2465789506 hasConceptScore W2465789506C125533998 @default.
- W2465789506 hasConceptScore W2465789506C126322002 @default.
- W2465789506 hasConceptScore W2465789506C127313418 @default.
- W2465789506 hasConceptScore W2465789506C144980905 @default.
- W2465789506 hasConceptScore W2465789506C164705383 @default.
- W2465789506 hasConceptScore W2465789506C170493617 @default.
- W2465789506 hasConceptScore W2465789506C187960798 @default.
- W2465789506 hasConceptScore W2465789506C2776670291 @default.
- W2465789506 hasConceptScore W2465789506C2779075594 @default.
- W2465789506 hasConceptScore W2465789506C2779134260 @default.
- W2465789506 hasConceptScore W2465789506C2780263000 @default.
- W2465789506 hasConceptScore W2465789506C2780930700 @default.
- W2465789506 hasConceptScore W2465789506C2781109936 @default.
- W2465789506 hasConceptScore W2465789506C44249647 @default.
- W2465789506 hasConceptScore W2465789506C535046627 @default.
- W2465789506 hasConceptScore W2465789506C71924100 @default.
- W2465789506 hasFunder F4320308573 @default.
- W2465789506 hasFunder F4320309555 @default.
- W2465789506 hasFunder F4320309974 @default.
- W2465789506 hasLocation W24657895061 @default.
- W2465789506 hasLocation W24657895062 @default.